NCT01513187 - Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

February 22, 2019

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG

Pazopanib + interferon alpha 2A

"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"

Trial Locations (13)

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Centro Integral Oncológico Clara Campal, PAU de Sanchinarro

31008

Clinica Univ. Navarra, Pamplona

33066

Hospital Central de Asturias, Oviedo

41009

Hospital Virgen de la Macarena, Seville

41013

Hospital Virgen del Rocio, Seville

45004

Hospital Virgen de la Salud, Toledo

46009

IVO, Valencia

08097

Instituto Catalán de Oncología, Hospitalet del Llobregat, L'Hospitalet de Llobregat

08003

Hospital del Mar, Barcelona

08036

Hospital Clínic, Barcelona

07010

Hospital Son Espases, Palma